Your Gut Microbiome May Determine How Well Radiotherapy Fights Cancer
Emerging evidence shows intestinal microbes profoundly shape immune responses to radiotherapy, opening doors to microbiome-based cancer therapies.
Summary
A 2025 review in Nature Reviews Clinical Oncology examines how the gut microbiome influences the effectiveness and toxicity of radiotherapy in cancer patients. Radiotherapy can stimulate anti-tumor immune responses, particularly when paired with immune-checkpoint inhibitors, but outcomes vary widely between patients. Evidence now suggests that intestinal microbial communities modulate this immune activity, affecting both treatment side effects and the ability of the immune system to target tumors. The authors explore how microbiome composition may serve as a predictive biomarker for treatment response and discuss potential therapeutic strategies — such as microbiome modulation — to enhance radiotherapy outcomes. This review highlights the gut-immune-tumor axis as a critical frontier in precision oncology.
Detailed Summary
Radiotherapy is a cornerstone of cancer treatment, valued for its ability to selectively destroy malignant cells. Beyond direct tumor killing, phase I–II clinical trials increasingly suggest that radiotherapy can stimulate systemic anti-tumor immune responses — a phenomenon of growing therapeutic interest, especially when radiotherapy is combined with immune-checkpoint inhibitors (ICIs). Yet patient responses remain highly variable, and the reasons are not fully understood.
This 2025 review by Chen, Deutsch, Kroemer, Galluzzi, and Zitvogel — all affiliated with leading cancer research institutions including Gustave Roussy — synthesizes two decades of accumulating evidence linking the intestinal microbiome to cancer immunosurveillance. The gut microbiota is now recognized as a key regulator of systemic immune tone, influencing responses to ICIs, CAR-T cell therapies, and other immunotherapies. The authors extend this framework specifically to radiotherapy.
The review critically discusses how microbial ecosystems affect both radiotherapy-induced toxicities (such as gastrointestinal damage) and the quality of tumor-targeting immune responses elicited by radiation. Certain microbial compositions appear to enhance immunostimulatory effects of radiotherapy, while others may blunt them or worsen side effects. These relationships suggest the microbiome could serve as a predictive biomarker for treatment sensitivity and adverse event risk.
Therapeutically, the authors highlight the potential of microbiome-targeted interventions — such as dietary modification, probiotics, prebiotics, or fecal microbiota transplantation — to optimize radiotherapy outcomes. Combining such strategies with ICIs and radiotherapy could represent a new multi-modal approach in precision oncology.
As a review drawing on earlier-phase trial data and preclinical evidence, definitive causal claims are limited. Large, prospective, randomized trials are needed to validate these associations and guide clinical implementation.
Key Findings
- Gut microbiome composition significantly influences immune responses triggered by radiotherapy in cancer patients.
- Certain microbial profiles may predict sensitivity or resistance to radiotherapy-immunotherapy combinations.
- Microbiota affects both the severity of radiotherapy-induced toxicities and anti-tumor immune efficacy.
- Microbiome modulation — via diet, probiotics, or FMT — is proposed as a strategy to enhance radiotherapy outcomes.
- Radiotherapy combined with immune-checkpoint inhibitors shows promise, with microbiome as a key modifying factor.
Methodology
This is a narrative review published in Nature Reviews Clinical Oncology, synthesizing preclinical studies and phase I–II clinical trial data. The authors critically evaluate existing literature on microbiota-radiotherapy interactions rather than presenting original experimental data. No meta-analysis or systematic review methodology is described.
Study Limitations
The review is based largely on phase I–II trial data and preclinical evidence, limiting the strength of causal conclusions. Prospective randomized trials validating microbiome biomarkers and therapeutic interventions in radiotherapy settings are lacking. Multiple authors report financial ties to pharmaceutical and biotech companies, which should be considered when interpreting emphasis and conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.